SCHEMBL201455

SCHEMBL201455

CC(Oc1ccc(C#N)cn1)C(=O)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.48
LMNA P02545 1/20 0.48
GABRA5 P31644 1/20 0.47
MAOB P27338 1/20 0.43
OPRM1 P35372 1/20 0.42
ACACB O00763 5/20 0.41
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
PGGT1B P53609 1/20 0.41
ALDH1A1 P00352 1/20 0.39
CTSL P07711 1/20 0.39
CTSS P25774 1/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CCNK O75909 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CDK12 Q9NYV4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3475298 0.81 CXCR2 (0.49) L3MBTL1LMNAGABRA5ACACBALDH1A1
SCHEMBL5557276 0.81 SLC22A12 (0.47) GABRA5ACACBTDP1
SCHEMBL3370056 0.78 L3MBTL1 (0.52) L3MBTL1LMNAALDH1A1TSHRTDP1
SCHEMBL202417 0.78 HSD11B1 (0.43) L3MBTL1GABRA5MAOBOPRM1FNTA
SCHEMBL1221481 0.76 MAOB (0.62) GABRA5MAOBOPRM1
SCHEMBL8411968 0.74 OPRM1 (0.57) L3MBTL1MAOBOPRM1ACACBALDH1A1
SCHEMBL16673428 0.72 LMNA (0.68) L3MBTL1LMNAALDH1A1TSHRTDP1
SCHEMBL2814424 0.71 ACACB (0.49) L3MBTL1GABRA5OPRM1ACACBALDH1A1
SCHEMBL11815950 0.71 L3MBTL1 (0.47) L3MBTL1LMNAGABRA5ACACBALDH1A1
SCHEMBL7357435 0.70 ALDH1A1 (0.53) L3MBTL1LMNAALDH1A1CTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088926-B2 Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity JENRIN DISCOVERY, INC. (US) 2012-01-03 US disclosed
WO-2008144604-A1 SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2008-11-27 WO disclosed
US-20080287505-A1 SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287505-A1 SUBSTITUTED 2-METHYL-2-PHENOXY-N-PROPYL-PROPIONAMIDES AS CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY CNR2, CNR1, GPR119 L3MBTL1 3370/4885LMNA 2674/4885GABRA5 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.